Recently, Gartner published the latest Market Guide for CRM in Pharma and Biotech. This is the second version of this guide focused on defining the CRM market in Pharma and Biotech and profiling vendors in the space.
A number of vendors were added and dropped during this market guide update process. Updated vendor profiles, market definition and direction reflects the latest information based on Gartner research and analysis. Key areas of focus for this update are; impact of IMS Health acquisition of Cegedim CRM assets, growth of Veeva market share and the continued march towards digital multichannel engagement.
Contact me to discuss the latest updates to the market guide and explore the impact on your organization.
Comments or opinions expressed on this blog are those of the individual contributors only, and do not necessarily represent the views of Gartner, Inc. or its management. Readers may copy and redistribute blog postings on other blogs, or otherwise for private, non-commercial or journalistic purposes, with attribution to Gartner. This content may not be used for any other purposes in any other formats or media. The content on this blog is provided on an "as-is" basis. Gartner shall not be liable for any damages whatsoever arising out of the content or use of this blog.